The coumarin scopoletin potentiates acetylcholine release from synaptosomes, amplifies hippocampal long-term potentiation and ameliorates anticholinergic- and age-impaired memory  by Hornick, A. et al.
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Neuroscience 197 (2011) 280–292THE COUMARIN SCOPOLETIN POTENTIATES ACETYLCHOLINE
RELEASE FROM SYNAPTOSOMES, AMPLIFIES HIPPOCAMPAL LONG-
TERM POTENTIATION AND AMELIORATES ANTICHOLINERGIC- AND
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Abstract—In a previous study the simple, naturally derived
coumarin scopoletin (SCT) was identified as an inhibitor of
acetylcholinesterase (AChE), using a pharmacophore-based
virtual screening approach. In this study the potential of SCT
as procholinergic and cognition-enhancing therapeutic was
investigated in a more detailed way, using different experi-
mental approaches like measuring newly synthesized acetyl-
choline (ACh) in synaptosomes, long-term potentiation (LTP)
experiments in hippocampal slices, and behavior studies.
SCT enhanced the K-stimulated release of ACh from rat
rontal cortex synaptosomes, showing a bell-shaped dose
ffect curve (Emax: 4 M). This effect was blocked by the
icotinic ACh receptor (nAChR) antagonists mecamylamine
MEC) and dihydro--erythroidine (DHE). The nAChR agonist
and AChE inhibitor) galantamine induced a similar increase
n ACh release (Emax: 1 M). SCT potentiated LTP in hip-
ocampal slices of rat brain. The high-frequency stimulation
HFS)-induced, N-methyl-D-aspartate (NMDA) receptor de-
endent LTP of field excitatory postsynaptic potentials at
A3-CA1 synapses was greatly enhanced by pre-HFS appli-
ation of SCT (4 M for 4 min). This effect was mimicked by
icotine (2 M) and abolished by MEC, suggesting an effect
n nAChRs. SCT did not restore the total inhibition of LTP by
MDA receptor antagonist D, L-2-amino-5-phosphonopen-
anoic acid (AP-5). SCT (2 g, i.c.v.) increased T-maze alter-
nation and ameliorated novel object recognition of mice with
scopolamine-induced cholinergic deficit. It also reduced age-
associated deficits in object memory of 15–18-month-old
mice (2 mg/kg sc). Our findings suggest that SCT possesses
memory-improving properties, which are based on its direct
nAChR agonistic activity. Therefore, SCT might be able to
1 These authors contributed equally to this work.
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In a previous study scopoletin (SCT) was identified as a
putative inhibitor of acetylcholinesterase (AChE) based on
a computer-aided screening approach. The coumarin was
found to fit to a structure-based pharmacophore model
constructed from interaction of galantamine to the enzyme
(Rollinger et al., 2004; Stuppner et al., 2005). However, in
vitro tests showed a rather high IC50 for AChE of 135 M.
Nevertheless SCT at low concentrations (2 M) was able
o enhance brain ACh in the rat brain (Rollinger et al.,
004) suggesting that the compound might possess addi-
ional properties. Among substances with coumarin scaf-
olds, several compounds can be found exerting memory-
meliorating properties. For example, nodakenin reduced
he memory deficit induced by the anticholinergic scopol-
mine (SCOP) in mice (Kim et al., 2007). Ensaculin, a
ynthetically modified natural coumarin, also showed anti-
ementia activity (Hoerr and Noeldner, 2002). Several
oumarin derivatives were reported to have inhibitory ac-
ivity at AChE, monoamino oxidase (MAO), or both (Shen
t al., 2005; Chimenti et al., 2004; Brühlmann et al., 2001).
dditionally, antioxidative properties were found for some
ompounds of this chemical class (Lin et al., 2008; Tiyagi
t al., 2005).
SCT has previously been described as an anti-inflam-
atory (Muschietti et al., 2001; Calixto et al., 2003) and
ntiproliferative agent (Fujioka et al., 1999) that exhibits
ctivities like the inhibition of inducible nitric oxide syn-
hase (Kim et al., 1999; Kang et al., 1999) and prostaglan-
in synthase (Farah and Samuelsson, 1992). It also inhib-
ts the MAO at moderate concentrations (Yun et al., 2001)
nd may act as an antioxidant (Shaw et al., 2003) and a
adical scavenger (Toda, 2002). Several drugs that bind to
ChE were shown to also interact with an allosteric binding
ite of nicotinic ACh receptors (nAChRs). This behavior
as also been reported for galantamine, which was used
s ligand template for the identification of SCT (Rollinger et
l., 2004). Therefore, it can be speculated that SCT might
Open access under CC BY-NC-ND license.ossess an affinity to nAChRs.
 license.
a
w
e
d
t
p
p
p
p
o
p
t
e
l
s
a
a
a
m
f
p
o
M
i
e
c
n
n
(
2
m
w
h
p
a
t
t
m
q
w
s
i
1
A
m
G
2
E
H
a
s
B
s
m
m
b
s
T
t
e
t
s
a
i
3
A. Hornick et al. / Neuroscience 197 (2011) 280–292 281A drug that enhances cholinergic neurotransmission
nd also exerts antioxidative and anti-inflammatory actions
ould be highly desirable as a therapeutic for neurodegen-
rative diseases such as Alzheimer’s dementia (AD). Ad-
itionally, nAChR agonists are of high interest because
hey may also decrease the in excess synthesis and de-
osition of beta-amyloid peptide (Buckingham et al., 2009).
The aim of our study was to investigate whether SCT
ossesses cholinergic transmission-enhancing, synaptic
lasticity-increasing, and cognition and memory-improving
roperties. For this purpose, we studied the effects of SCT
n ACh release from brain cortex synaptosomes, on hip-
ocampal long-term potentiation (LTP) and in behavioral
asks, which are sensitive to procholinergic drugs.
Cholinergic nerve endings in the frontal brain cortex
xpress nicotinic autoreceptors, which enhance ACh re-
ease. Hence, synaptosomes from this brain area are well
uited to investigate the mechanism of putative nAChR
gonists (Tzavara et al., 2003; Zhang et al., 2002; Duffy et
l., 2009; Roman et al., 2004; Raiteri et al., 1974; Marchi et
l., 1999). The hippocampus is central to learning and
emory, and it is known that nAChRs contribute to these
unctions (Jones et al., 1999). LTP is a form of synaptic
lasticity, which is thought to underlie learning and mem-
ry processes (Bliss and Collingridge, 1993; Martin and
orris, 2002). Congruently, hippocampal LTP is impaired
n aged animals, in cholinergic deficit, and in animal mod-
ls of AD (Froc et al., 2003). Numerous agents including
holinergic enhancers and nAChR agonists show procog-
itive properties in vivo and are also effective in promoting
eurotransmission and/or LTP in hippocampal slices
Lynch, 2002; Lagostena et al., 2008; Sliwinski et al.,
004). We investigated the effects of SCT in learning and
emory tasks in aged mice and in mice rendered amnesic
ith the anticholinergic scopolamine. This pretreatment
as been widely used for the detection of nootropic and
rocholinerigic activity of agents such as AChE inhibitors
nd nAChR agonists. The alternation rate in T-maze and
he recognition of novel objects vs. familiar ones is sensi-
ive to inhibition and stimulation of cholinergic neurotrans-
ission (Kokkinidis and Anisman, 1976; Delatour and Gis-
uet-Verrier, 1996). The T-maze task measures spatial
orking memory function while the object recognition mea-
ures a nonspatial memory with the characteristics of ep-
sodic memory (Gerlai, 1998; Ennaceur and Delacour,
988). Both forms of memory are impaired in the course of
D with episodic memory generally being the first and
ost severely affected one (Desgranges et al., 1996;
ainotti et al., 1998; Petersen et al., 2000; Remy et al.,
005).
EXPERIMENTAL PROCEDURES
Ethical statement
The experimental procedures and number of animals used in this
study were approved by an ethical committee at the Federal
Ministry of Science and Research of the Republic of Austria and
conducted according to the Directive of the European Communi-
ties Council of 24 November 1986 (86/609/EEC). The experi- wments were designed in such a way that the number of animals
used and their suffering was minimized.
Drugs and chemicals
[3H]-choline (0.03 M, 17.5106 Bq/g was purchased from New
ngland Nuclear, Boston, MA, USA). D, L-2-amino-5-phosphono-
pentanoic acid (AP-5), galantamine hydrobromide, mecamyl-
amine hydrochloride (MEC), dihydro--erythroidine (DHE), and
scopolamine hydrobromide (SCOP) were from Tocris BioScience,
Bristol, UK. Picrotoxin was bought from Research Biochemicals
International, Natick MA, USA. Atropine sulfate, acetylcholine hy-
drochloride (ACh), ()-nicotine, and SCT were purchased from
Sigma, St. Louis, MO, USA.
Synaptosomes
Preparation. Synaptosomes were prepared from the brain
frontal cortex of male Sprague–Dawley rats (4 months old, Re-
search Institute for Laboratory Animal Breeding, University of
Vienna, Himberg, Austria). The pellet between 1000 and 15000 g
of a 0.32 M sucrose homogenate was collected and resuspended
in basal medium (mM: NaCl 125, KCl 3, MgSO4 1.2, CaCl2 1.2, Na
2PO4 1.0, NaHCO3 22, and glucose 10), aerated with 95%
O2-5% CO2 at 37 °C, pH 7.2–7.4 (Raiteri and Raiteri, 2000).
Superfusion protocol. The synaptosomal suspension was
incubated with [3H]-choline (0.03 M, 17.5106 Bq/g) for 15 min
t 37 °C and then diluted aliquots were applied on filters in a
uperfusion system maintained at 37 °C (Raiteri et al., 1974).
asal and stimulation media (basal medium with 15 mM K) were
supplemented with 1 M ACh and 0.1 M atropine. After a pre-
superfusion period of 30 min, the synaptosomes showed a con-
stant outflow of newly synthesized [3H]-ACh (Marchi et al., 1983).
The K-stimulated release of [3H]-ACh was determined in two
ubsequently collected fractions of 6 min. Fraction 1 (control): 6
in of superfusion with basal medium, fraction 2 (stimulation): 1.5
in of superfusion with stimulation medium followed by 4.5 min
asal medium. SCT and galantamine were diluted from stock
olutions prepared with a minimum of dimethyl sulfoxide (DMSO).
hese drugs were present in the superfusion medium concomi-
antly with 15 mM K (for 1.5 min). Antagonists MEC and DHE
were present from 8 min before stimulation throughout the
experiment.
Statistical analysis. The amount of [3H]-ACh released in
ach sample was calculated as fraction of the total synaptosomal
ritium at the start of the respective collection period (tritium in the
ample/sum of tritium in the respective fractions and in the syn-
ptosomes on the filter). K-evoked release was expressed as
percentage of basal release rate. Each n represents the mean of
an experiment with one synaptosomal preparation in at least three
superfusion chambers. Statistical significance of group variances
was calculated by one-way analysis of variance (ANOVA) fol-
lowed by Bonferroni’s test.
Hippocampal slices
Preparation. Coronal brain slices containing hippocampi
(thickness, 400 m) were prepared from Sprague–Dawley rats
(65–104 g body weight). After decapitation the brains were re-
moved and sectioned at 0 °C on a vibroslicer in artificial cerebro-
spinal fluid (CSF; composition in mM: NaCl 120, KCl 2.5, MgSO4
2.0, NaH2PO4 1.25, NaHCO3 26, CaCl2 2, glucose 10) aerated
with 95% O2-5% CO2 to a final pH of 7.35. Slices were then placed
n a maintenance chamber and slowly warmed up from 16 °C to
0 °C (Capron et al., 2006).
Recording of evoked fEPSPs. After 1.5 to 3 h the slices
ere transferred to an interface-type chamber (BSC-2, Automate
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A. Hornick et al. / Neuroscience 197 (2011) 280–292282Scientific) and superfused with 100 M picrotoxin-containing CSF
at 1 ml/min at 30 °C. The Schaffer collateral tract was electrically
stimulated with a bipolar electrode. fEPSPs in the CA1 region
were evoked by pulses at 30% of maximally effective strength at
a frequency of 0.05 Hz. LTP was evoked by high-frequency stim-
ulation (HFS) with one train of pulses at a frequency of 100 Hz for
1 s at 60% of maximal effective strength. fEPSPs were recorded
with a glass electrode (1–2 M resistance, filled with CSF), filtered
between 2 and 5 kHz, and recorded with pClamp9 (Electrophys-
iology Data Acquisition and Analysis Software, Axon Instruments).
Drugs. Stock solutions of drugs were prepared as solutions
in CSF (nicotine, MEC, AP-5) and DMSO (SCT, galantamine) as
required and diluted immediately before use. Control experiments
were carried out with solutions containing the same concentra-
tions of DMSO as the respective drug solution.
Statistical analysis. fEPSP amplitude was calculated off-
line and normalized to the mean of 10 min prior to HFS. Statistical
analysis was carried out by ANOVA followed by Bonferroni post
hoc test.
Memory and behavior
Animals. C56BL/6N male, 4–6-month-old and 16–18-
onth-old mice (Charles River Laboratories, Sulzfeld, Germany),
ere used in the behavioral studies. The mice were housed in
roups of four in cages (40 (L)25 (W)15 (H) cm3) at constant
umidity (50–55%) and temperature (221 °C) on a 12:12 h
ight/dark cycle (7:00–19:00 h), with food and water ad libitum.
ounger mice (4–6 months) were implanted with i.c.v. cannulas
or application of SCOP and SCT. The aged mice were injected
ith SCT by the s.c. route.
Surgery. The 4–6-month-old mice were anesthetized with
entobarbital sodium (60 mg/kg, i.p.) and a guide cannula (gauge
5, o.d. 0.52 mm, i.d. 0.26 mm, and 7 mm long) was stereotaxi-
ally implanted into the brain area 0.5 mm higher than the lateral
erebral ventricle (0.1 mm posterior, 0.8 mm lateral to bregma,
2.2 mm ventral to the dura) (Franklin and Paxinos, 1997). Each
nimal was allowed to recover for 5 days prior to experimentation.
Experimental design and drug treatment. Experiments
ere conducted between 8:00 and 16:00 h. Mice with i.c.v. can-
ulas were randomly divided into four experimental groups: vehi-
le; SCOP 20 g; SCT 2 g; and SCOP 20 g plus SCT 2 g. The
rugs were applied in 1 l of vehicle solution (SCOP: saline, SCT:
DMSO: 7 sterile water). I.c.v. injections were carried out 15 min
efore the start of the tests. Aged mice obtained SCT s.c. 30 min
rior to object memory test (vehicle: 1 DMSO: 1 EtOH, diluted with
live oil as required).
T-maze continuous alternation experiments. Alternation be-
avior was tested under dimmed illumination (40 lx) in a T-maze
quipped with guillotine doors at the start box and at the entrances
f the T-arms as described by Gerlai (Gerlai, 1998).
Testing started with a forced-choice trial in which one of the
oal arms was blocked by a guillotine door. A mouse was arrested
n the start box. The door of the box was opened after 10 s, and
he mouse was allowed to explore the open arm. After return the
ouse was confined for 5 s by lowering the guillotine door. The
ubsequent 14 trials were “free-choice” trials in which the two
oors of the goal arms were open. After a mouse entered one goal
rm, the direct entrance into the other one was blocked by closing
he door. After each return to the start box, the mouse was again
onfined for 5 s. A session was terminated as soon as 14 free-
hoice trials had been performed or when 30 min had elapsed.
The percentage of alternation for each mouse was calculated
s the ratio of the actual number of alternation to the possible
umber (defined as the total number of arm entries minus one) *ultiplied by 100. The time required to finish the 14 trials (running
ime) was also registered.
Novel object recognition task. The novel object recognition
ask was performed as described by Ennaceur and Delacour
1988). Each mouse was habituated to the test box for 10 min in
he absence of objects. During training session (T1) on the fol-
owing day, two identical objects were placed in the back corners
f the box, and behavior including exploration of the two objects
as recorded for 10 min. After 18 h during testing trial (T2), a
ovel object replaced one of the objects now familiar to the mouse
resented in T1, and the mouse was again allowed to explore for
0 min. An additional group of mice was tested after a forgetting
nterval of 3 h. The times spent by mice in exploring each object
uring experiment were analyzed on recorded videos. Exploration
as defined as directing the nose toward the object at a distance
f less than 1 cm or touching the object with its forepaw or nose.
Measures of retention in this task are object exploration time
atio (object exploration time with a novel object during testing
ivided by object exploration time with a familiar object during
esting) and discrimination index (difference in exploration time
xpressed as a proportion of the total time spent exploring the two
bjects in T2). These data were calculated as previously de-
cribed (Ennaceur and Delacour, 1988; Hornick et al., 2008).
Open-field test. Open-field behavior was investigated in a
ox of 414141 cm3 at illumination strength of 100 lx. Behaviors
were recorded with an activity monitoring system based on infra-
red photobeams. The time of locomotor activity, the overall dis-
tance traveled by the mice, and the activity in the central zone
(2828 cm2) were monitored for 10 min (Prut and Belzung, 2003).
RESULTS
Release study
A 1.5-min pulse of 15 mM K at the start of the 6 min of the
stimulation sample increased ACh release by 292.8
30.0% of the basal release measured in the preceding
sample (Fig. 1). This effect was half maximal at most since
30 mM K increased ACh release by 629.473.3% (n4)
ver basal release (not shown). SCT added to the stimu-
Fig. 1. Effect of scopoletin (SCT) on 15 mM K-induced release of
[3H]-ACh from prefrontal cortex synaptosomes and inhibition by the
ntagonists MEC and DHE. The medium contained 1 M ACh and 0.1
M atropine. Bars represent K-evoked release as percentage of
asal release, meanSEM. Each n represents number of experiments
one in triplicate. ANOVA and Bonferroni post hoc test, * P0.05,
** P0.001 from control, ## P0.01 from SCT 4 M.
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A. Hornick et al. / Neuroscience 197 (2011) 280–292 283lation medium at the concentrations 2, 4, and 10 M
enhanced the 15 mM K-evoked release showing a curve
ith maximum at 4 M (595.659.6%). The presence of
EC (100 M) and of DHE (10 and 1 M) in the medium
locked the potentiation of ACh release induced by SCT
Fig. 1). The antagonists alone did not influence 15 mM
-induced release (not shown. MEC: 275.144.6%,
n4; DHE: 301.629.8%, n3). SCT did not influence
ACh release under the basal, nonstimulating K concen-
tration of 3 mM (Fig. 2). The potentiation of K-evoked
ACh release was also found with galantamine, also show-
ing a bell-shaped dose dependency. The maximal effect
was observed at 1 M (607.972.1%) and was also
blocked by MEC (100 M) (Fig. 3).
lectrophysiological study
Basal neurotransmission. The effect of SCT on basal
eurotransmission and neuronal plasticity was investi-
ated in rat hippocampal slices. fEPSP was evoked in the
A1 subregion by stimulation of Schaffer collaterals. SCT
id not influence the basal fEPSP amplitude when applied
t concentrations of 4 and 20 M. Only the relatively high
concentration of 200 M SCT (not used in the LTP study)
enhanced fEPSP amplitude under basal conditions
(180.313.8% of control, n4; not shown). Nicotine at
concentrations of 2 and 10 M and the antagonists MEC
10 M) and AP-5 (100 M) did not influence the magni-
tude of the basal fEPSP amplitude (not shown).
Effect of nicotine and SCT on LTP. HFS of Schaffer
collaterals (100 Hz for 1 s) under drug-free conditions
induced a pronounced LTP. Immediately after HFS the
fEPSP amplitude increased on an average to 197.9
19.7% of the pretetanus value and stabilized at a level of
136.77.4% (Figs. 4A, B and 5A, B). HFS-induced LTP
was N-methyl-D-aspartate (NMDA) receptor dependent
Fig. 2. Effect of scopoletin (SCT) on basal (non-stimulated) release of
[3H]-ACh from prefrontal cortex synaptosomes. The medium contained
M ACh and 0.1 M atropine. Bars represent cumulative release as
of total [3H]-ACh present in the synaptosomes on the filter at the
eginning of superfusion, meanSEM. Number of experiments done
n triplicate (n) was four.since in presence of the antagonist AP-5 only a short-termpotentiation was expressed (immediate peak amplitude of
176.617.2% followed by a rapid decline to nonpotenti-
ated basal values within 10 min; n4; not shown). Nicotine
applied to the slice pre-HFS for 4 min at the concentration
of 2 M potently enhanced the HFS-induced LTP. The
gonist induced an increase of the fEPSP amplitude during
he immediate peak phase to 278.148.9% of control
alue. After the period of decline the stabilized amplitude
as still at an elevated level (171.66.1%) (Fig. 4A, B).
Also SCT induced a potent facilitation of hippocampal
TP. 4 M (4 min pre HFS) boosted fEPSP amplitude to
247.719.1% and also the stabilized maintenance level of
fEPSP was substantially higher than that after drug-free
induction (192.45.9%) (Fig. 5A, C). The nicotinic AChR
antagonist MEC abolished this potentiating effect of SCT
to values not significantly different from drug-free condi-
tions (158.39.0%) (Fig. 5A, C). The above mentioned
inhibition of HFS-induced LTP by AP-5 was not rescued by
SCT. In presence of AP-5 and treatment of SCT (4 M),
he HFS induced just a short potentiation, in magnitude
nd fast decline not differing from the effect produced by
P-5 alone (maximal amplitude 183.320.1%, steady-
tate phase 100.78.7% of control) (Fig. 5).
ehavioral study
Effect of SCT i.c.v. on T-maze alternation. SCT and
COP did not disrupt normal behavior. Cholinergic symp-
oms such as salivation, lacrimation, tremor, and diarrhea
ere not observed at drug concentrations used in this
tudy.
Each mouse was subjected to one forced-choice trial
ollowed by free-choice trials. Control mice selected the
ovel arm of the maze at a rate significantly above chance
59.33.3%, n11, P0.05, Wilcoxon test). The dose of
CT in behavioral testing was estimated in pilot experi-
ents, revealing ineffectiveness of concentrations below
Fig. 3. Effect of galantamine (GT) on 15 mM K-induced release of
3H]-ACh from prefrontal cortex synaptosomes and inhibition by MEC
100 M). Bars represent K-evoked release as percentage of basal
release, meanSEM. Each n represents the number of experiments
done in triplicate. ANOVA and Bonferroni post hoc test, * P0.05,
*** P0.001 from control; # P0.05, ## P0.01 from GT 1 M.
S
w
u
i
c
a
a
B
t
5
u
t
d
b
t
(
s
T
t
7
i
d
7
t
b
i
A
e
m
l
t
st. * P0
A. Hornick et al. / Neuroscience 197 (2011) 280–2922840.4 g (n5, not shown). However, mice injected with 2 g
CT showed an increased alternation rate of 71.32.5%,
hich indicates an enhanced preference for entering the
nfamiliar maze arm (Fig. 6A). The running time was not
nfluenced (Fig. 6B). In contrast to the coumarin, the anti-
holinergic drug SCOP induced a pronounced decrease in
lternation rate to a value below chance level (37.02.4%)
nd an increase in running time (143.211.2%) (Fig. 6A,
). SCT reversed this SCOP-induced effect to values sta-
istically not different from controls (alternation rate:
8.32.6; running time: 116.49.8%) (Fig. 6A, B).
Effect of SCT on object recognition. Following habit-
ation to the arena, two identical objects were presented to
he mouse during T1, and a novel and a familiar object
uring T2. Exploration times during T1 were not different
etween vehicle- and drug-treated groups, indicating that
he treatments did not influence the inspection of objects
Figs. 7A and 8A).
Effect on SCOP-induced amnesia. Control mice
pent an equal time exploring the two identical objects in
1 (not shown) but more time exploring the novel object
han the familiar object after the 18-h interval in T2 (Fig.
B). This group of mice achieved a mean discrimination
ndex of 0.2870.030 showing that they were able to
iscriminate well between familiar and novel objects (Fig.
C). These mice did not yet reach the state of forgetting
he objects since their performance was not significantly
elow that of mice tested after a 3-h interval (discrimination
ndex: 0.3140.048, n8; not shown). SCOP (20 g,
i.c.v.) induced a drastic impairment of learning. The mice of
this group did not discriminate at all between the novel
object and the familiar object in the T2 (discrimination
index: 0.0290.019) (Fig. 7B, C). The exploratory activity
was not impaired since the exploration time showed no
significant difference to that of vehicle-treated control mice.
Fig. 4. Effect of nicotine on HFS-induced LTP. (A) Time course
representative fEPSPs recorded at the indicated time (1) before HFS a
measured 30–40 min after HFS. ANOVA and Bonferroni post hoc teSCT (2 g, i.c.v.) did not improve the object recognition of anormal mice (discrimination index: 0.3040.034). How-
ever, it abolished the amnestic effect of SCOP. It potently
increased the exploration ratio and discrimination index to
values not significantly different from the control
(0.2190.039), indicating restoration of learning and mem-
ory abilities to a large extent (Fig. 7B, C).
Effect on age-induced impairment. Aged mice
showed the required interest in the objects in T1 and T2
(6.930.73 and 6.660.55 s) (Fig. 8A). However, despite
a short interval of 3 h, they did not show preferential
exploration of the novel objects in T2 (exploration ratio:
0.9350.106) (Fig. 8B). Apparently they were not able to
discriminate novel objects from familiar ones (index:
0.0240.050) (Fig. 8C). SCT (2 mg, s.c.) clearly restored
the ability of these mice to recognize objects (ratio:
1.9260.396, index: 0.2700.053).
Effect of SCT on open-field locomotor behavior. The
anticholinergic scopolamine enhanced locomotor activity
in the open field as shown by the increase in the locomo-
tion indexes, such as travel distance, travel time, and
activity in the center area. Treatment with SCT exerted no
significant effect on the locomotion indexes. SCT did also
not influence the scopolamine-induced increase in travel
distance and duration (Table 1).
DISCUSSION
SCT enhances ACh release from brain
synaptosomes
In our study SCT potentiated the K-evoked release of
Ch from superfused frontal cortex synaptosomes. This
ffect was abolished by the nAChR antagonist MEC and
imicked by galantamine. The nonstimulated, basal re-
ease was not influenced by drug concentrations used in
his study. These findings suggest that the coumarin exerts
P amplitudes. Percentage of change, meansSEM. Inserts show
er HFS. (B) Percentage of change (meansSEM) in fEPSP amplitude
.05 vs. control.of fEPS
nd (2) aftn agonistic effect at nAChRs located at the synaptosomal
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is a very weak AChE inhibitor (EC50: 100 M), but AChE
inhibition and muscarinic autoreceptors are not involved in
this effect. Release-enhancing nAChRs and release-inhib-
iting muscarinic autoreceptors coexist on the cholinergic
nerve terminals in cortex (Szerb et al., 1977; Marchi et al.,
1983; Duffy et al., 2009). However, we blocked muscarinic
receptors with atropine. Interaction of drugs with AChE
does not alter ACh concentration in the superfusate be-
cause the released ACh is rapidly removed from the mem-
brane surface (Garcia-Sanz et al., 2001).
Under basal, nonstimulated conditions SCT at concen-
trations below 10 M did not affect the ACh release. It
shares this property with galantamine. As mentioned in the
introduction, SCT was found to fit to a pharmacophore
model that had been generated from the binding of galan-
tamine to the AChE (Rollinger et al., 2004). Galantamine
and the structurally similar compounds physostigmine and
codeine were shown to bind not only to AChE but also to
an allosteric binding site of nAChRs (Storch et al., 1995;
Fig. 5. Effect of scopoletin (SCT) and antagonists MEC and AP-
meansSEM. (B) Representative fEPSPs recorded at the indicated tim
in fEPSP amplitude measured 30–40 min after delivery of HFS. Nico
vs. control, # P0.05 vs. SCT.Samochocki et al., 2003). Hence, SCT and the three com-pounds mentioned above might share molecular domains
which provide affinity to an allosteric site of nAChRs.
Galantamine has no intrinsic activity per se, but it
enhances the effect of ACh on nAChRs (Samochocki et
al., 2003). Hence, the effect of SCT and galantamine on 15
mM K-evoked ACh release was investigated in presence
f 1 M extrasynaptosomal ACh. This concentration pro-
vides a low degree of activation of nAChRs, which does
not lead to a significant desensitization (Roman et al.,
2004). SCT induced a pronounced increase in the K-
voked release, and this effect was abolished by MEC and
HE. At the concentrations used in this study, DHE has
electivity for  and  subunits containing nAChRs and
does not influence 7 homomeric nAChRs (Papke et al.,
008). Hence, nn-nAChRs might be responsible for the
otentiating effect of SCT on ACh release. The effect of
CT resembles that of galantamine. Both agents stimu-
ated K-evoked release with an apparently bell-shaped
concentration-effect curve, and the maximum enhancing
concentration of SCT (4 M) was not far from that of
P. (A) Time course of fEPSP amplitudes. Percentage of change,
fore HFS and (2) after HFS. (C) Percentage of change (meansSEM)
own for comparison. ANOVA and Bonferroni post hoc test. * P0.055 on LT
e (1) begalantamine (1 M). At higher concentrations the release-
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tributed to desensitization of nAChRs. This has been dem-
onstrated with galantamine in electrophysiological studies
(Maelicke et al., 2000; Samochocki et al., 2003).
SCT amplifies hippocampal LTP
In our experiments HFS stimulation of Schaffer collaterals
induced an LTP of evoked fEPSPs in the CA1 region. LTP
showed NMDA glutamate receptor-dependent character-
istics since in presence of the antagonist the initially po-
tentiated fEPSPs decreased rapidly to the basal level.
It has been reported that this form of hippocampal LTP
is amplified by nicotine (1 to 5 M) and other nAChR
agonists (Nakauchi et al., 2007; Fujii et al., 2000). Also
under our experimental conditions the HFS-induced,
NMDA-dependent LTP was strongly enhanced by nicotine
when it was present during HFS. Nicotine increased the
magnitude of LTP to a new maximum, which was not
attained by stimulation alone. Other investigations found
nicotine boosts short-term potentiation to LTP (Ge and
Dani, 2005; Rosato-Siri et al., 2006) and enables LTP in
slices from aged animals with impaired synaptic plasticity
(Fujii and Sumikawa, 2001).
After showing the effect of nicotine on LTP, we tested
whether SCT exerts similar properties. Findings with gal-
antamine suggested that the potency of nAChR agonists to
enhance synaptosomal ACh release parallels the potency
to amplify hippocampal LTP. In our study with synapto-
somes, 1 M galantamine induced the maximum of ACh
release, and furthermore, this concentration was recently
reported to amplify hippocampal LTP (Moriguchi et al.,
2009). Hence, we investigated the effect of SCT on LTP at
4 M, the Emax. of K
-induced ACh release from cortex
synaptosomes found in this study.
In our experiments SCT showed a strong effect on
stimulation-evoked synaptic plasticity. It induced a pro-
nounced amplification of LTP very similar to the effect of
nicotine. This amplification was abolished by MEC, and
Fig. 6. Effect of scopoletin on T-maze alternation in scopolamine-amn
Scopolamine (SCOP; 20 g i.c.v.). Data are shown as meansSEM, a
est. * P0.05, ** P0.01 vs. control group; ## P0.01 vs. SCOP groSCT failed to rescue the inhibition of LTP by AP-5. These Skey findings suggest that SCT enhances NMDA-depen-
dent LTP through agonistic action at nAChRs. Several
other nAChR agonists, which were shown to improve
memory, also potentiated LTP in CA1 or dentate gyrus
(Newhouse et al., 2001; Lagostena et al., 2008; Timmer-
mann et al., 2007).
The action of nAChR agonists depends largely on
affected subtypes of nicotinic receptors, their location on
the different neurons, and the mutual interaction between
these cells. The hippocampus is endowed with nAChRs
predominantly of the homomeric 7 and the heteromeric
42 subtype (Alkondon and Albuquerque, 1993, 2004).
he nicotinic potentiation of LTP in CA1 was found to be
ediated mainly by the 7 subtype (Mann and Greenfield,
2003). However, it was also reported that both subtypes
contribute to the facilitating effect suggesting that cogni-
tion-enhancing agents can act through each one of these
nAChRs (Lagostena et al., 2008; Matsuyama and Matsu-
moto, 2003; Nakauchi et al., 2007). Recently, Moriguchi et
al. showed under experimental conditions very similar to
ours that galantamine potentiates NMDA-dependent LTP
in CA1 of hippocampal slices via the 7 subtype (Moriguchi
t al., 2009). The underlying intracellular mechanism
eems to consist in a potentiation of NMDA-induced cur-
ents in a PKC-dependent manner. The experiments with
ynaptosomes show that SCT activates  subunit contain-
ng DHE-sensitive subtypes. Whether SCT is selective for
hese subtypes or influences also 7 nAChRs remains to
e investigated.
ffects of SCT on memory and behavior
AChR agonists and the AChE inhibitors dose depend-
ntly increase alternation in the T-maze, ameliorate ob-
ect recognition, and decrease locomotor activity in the
pen field (Bontempi et al., 2003; Spowart-Manning and
an der Staay, 2004; Sambeth et al., 2007; Pichat et al.,
007; Syenkiewicz-Jarosz et al., 2000). A useful dose of
e. (A) Alternation rate, (B) running time. Scopoletin (SCT; 2 g i.c.v.);
f variance (ANOVA) followed by multiple comparisons Tukey–Kramerestic mic
nalysis oCT for the behavioral investigations was estimated in
s
p
E Data are
m . control
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the T-maze continuous alternation task (Bontempi et al.,
2003).
Fig. 7. Effect of scopoletin on object recognition in scopolamine-amn
xploration time, (B) Exploration ratio, and (C) Discrimination index.
ultiple comparisons Tukey–Kramer test. ** P0.01, *** P0.001 vs
Fig. 8. Effect of scopoletin on object recognition in aged mice. Scop
iscrimination index. Data are shown as meansSEM. Statistical analysis byT-maze alternation. This one trial test is well suited to
tudy the effects of drugs on the cholinergic system. When
laced in a T-maze, rats possess a strong tendency to
e. Scopoletin (SCT) 2 g i.c.v., scopolamine (SCOP) 20 g i.c.v. (A)
shown as meansSEM, analysis of variance (ANOVA) followed by
group; ## P0.01, ### P0.001 vs. SCOP group.
CT) 2 mg/kg s.c. (A) Exploration time, (B) Exploration ratio, and (C)estic micoletin (S
t-test. * P0.05.
2A
A. Hornick et al. / Neuroscience 197 (2011) 280–292288alternate arm choices on successive trials. Testing of mice
is not trivial since several strains are fearful in the novel
situation, which may interfere with performance (Bertholet
and Crusio, 1991; Dember, 1990; Spowart-Manning and
van der Staay, 2004). In our experiments, the C57BL/6N
mice showed alternating choices of right and left maze
arms at a rate significantly above chance, indicating low
anxiety and a clear expression of spatial memory in their
behavior. The spontaneous alternation test is sensitive to
the consequences of normal and pathological aging (Stone
et al., 1992; Willig et al., 1987). Neurochemical pathways
using ACh and dopamine in the septum and hippocampus
have been implicated in the exploration of novel maze
arms (Kokkinidis and Anisman, 1976; McFarland, 1989;
Einat and Szechtman, 1995). Spontaneous alternation
rates were often shown to be decreased by drugs that
impair cholinergic transmission (Meyers and Domino,
1964; Kokkinidis and Anisman, 1976). In contrast, nAChR
agonists including nicotine enhance alternation rate of
aged and scopolamine-amnestic mice (Bontempi et al.,
2003). Furthermore, AChE inhibitors increase alternation
rate in untreated and pirenzepine-impaired animals (Dela-
tour and Gisquet-Verrier, 1996; Egger et al., 1973; Ukai et
al., 1995). Consistent with these reported effects of nAChR
agonists and AChE inhibitors, SCT enhanced the alter-
nation rate in untreated mice and reversed the scopol-
amine-induced decrease to control levels. The procho-
linergic effect might be interpreted as facilitation of spa-
tial working memory, required to recognize the
previously entered arm of the maze. However, the effect
of scopolamine to reduce the alternation rate below
chance level suggests that a modulation of neophobic
behavior might also be involved in the effects of the
anticholinergic and of SCT.
Novel object recognition. In our study, we also used
the novel object recognition task. This paradigm reveals
the ability of the animals to recognize the objects they have
seen only once during the training trial. Normal mice have
a natural propensity to explore novel objects, and when
this bias is observed it is inferred that mice remember the
familiar object. This kind of object recognition is based on
a nonspatial memory with the characteristics of episodic
memory (Ennaceur and Delacour, 1988), a form of mem-
ory that is primarily affected in senile dementia, age-asso-
ciated impairment, and the Alzheimer’s type of dementia
Table 1. Effect of scopoletin (SCT) on locomotor indexes in the open-fi
0 g i.c.v., n8–12 animals per group
Mice Treatment Move distance (cm)
ge of 4–6 mon,
SCT and SCOP
i.c.v.
Control 3240221
SCT 2987176
SCOP 4039201*
SCTSCOP 4416146*
Age of 15–18 mon,
SCT s.c.
Control 2018189
SCT 2286325
Data are shown as meansSEM, analysis of variance (ANOVA) fo
* P0.05 vs. control group.(Flicker et al., 1985; Lee et al., 2003). Also in mice andrats, object discrimination appears to depend on the integ-
rity of the cholinergic system (Bartolini et al., 1996; Dodart
et al., 1997) since AChE inhibitors and nAChR agonists
ameliorate memory in this task. Galantamine improved
impairments of object recognition induced by beta-amyloid
or lesion of magnocellular nucleus basalis (Wang et al.,
2007; Rispoli et al., 2006). Nicotine, the 7 nAChR agonist
SEN12333 and donepezil improved object memory in sco-
polamine-treated rats (Sambeth et al., 2007; Roncarati et
al., 2009).
Effectiveness of SCT in states of cholinergic deficit was
investigated with the widely used scopolamine paradigm
and in 15–18-month-old mice. Numerous studies have
shown that scopolamine injected i.p. or s.c. disrupts object
recognition. Also our results indicate that 20 g scopol-
amine injected i.c.v. practically abolishes object memory in
C57BL/6N mice. We show that even this total disruption of
memory by the anticholinergic is almost restored by 2 g
SCT, suggesting a potent ameliorating action of SCT on
the impaired cholinergic transmission.
In some studies nAChR agonists caused improve-
ments of object recognition in normal, unimpaired mice;
however, this was not the case in our study (Boess et al.,
2007; Puma et al., 1999; Pichat et al., 2007; Wishka et al.,
2006). The 4–6-month-old C57 BL6 mice used in our
study may not have reached the state of forgetting the
familiar objects within the delay interval of 18 h. In contrast,
the 16–18-month-old mice were not able to retain the
object memory for the interval of 3 h, a finding which
indicates a severe age-associated impairment. Neverthe-
less, SCT applied s.c. caused a pronounced improvement
of object recognition, showing its potential as memory
enhancer and its property to reach the brain when admin-
istered systemically.
Open-field behavior. In the open-field paradigm SCT
had neither a significant effect on move distance and time
nor on the anxiety state-related locomotion in the center
area. Also the locomotor indexes of the object memory test
and of the alternation test were not significantly influenced
by the drug, suggesting that the outcome depended on
task-specific performance and learning abilities and not on
unspecific influences. The amnesic agent SCOP en-
hanced locomotor activity, although we tried to keep the
dose as low as possible. It has been shown that manipu-
lations of the cholinergic brain systems affect open-field
igm. Scopoletin (SCT) 2 g i.c.v.; 2 mg/kg s.c., scopolamine (SCOP)
ove time (s) Center distance (%) Center time (%)
72.512.9 15.043.41 18.026.71
53.513.7 17.992.68 20.424.19
97.89.6 13.653.27 16.865.17
96.715.1 16.034.53 19.306.75
88.725.6 20.375.82 21.113.17
09.234.8 23.184.77 22.572.73
multiple comparisons Tukey–Kramer test.eld parad
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field. In contrast, nAChR agonists and AChE inhibitors
have been reported to reduce spontaneous locomotor ac-
tivity and counteract the stimulatory effect of antagonists
such as scopolamine (Bontempi et al., 2003; Carlsson and
Carlsson, 1989; Capone et al., 1999). In our study, SCT
did not reduce scopolamine-evoked activity. Presum-
ably the dose was too low to exert the antiscopolamine
effect. The mechanism implicated in scopolamine-in-
duced hyperactivity is different from the mechanism im-
plicated in the scopolamine-induced memory deficit and
probably related to a dopaminergic system interaction
(Fernando et al., 1986; Itoh et al., 1993). Hence, the
locomotor activation may be more resistant to nAChR-
mediated enhancement of cholinergic transmission than
the memory deficit.
To summarize, the pharmacological properties of SCT
found in this study suggest that this molecule might be
useful in the treatment of brain disturbances associated
with dementia, such as AD. The main features of AD are
progressive memory deterioration and disordered cogni-
tive function resulting from loss of cholinergic transmission.
In a significant proportion of AD patients, there is also a
slowing of motor activity and extrapyramidal dysfunction
resembling those seen in Parkinson’s disease and behav-
ioral abnormalities. Depressive symptoms occur in a large
proportion of subjects with AD and other types of demen-
tia, and this may be related to degeneration of noradren-
aline and serotonin neurons innervating the limbic system
(Newman, 1999; Palmer et al., 1988). The MAO inhibitory
property of SCT might exert a beneficial effect against
these catecholaminergic impairments. Yet AChEs includ-
ing also the nAChR agonistic galantamine and the NMDA
antagonist memantine are still the only drugs that produce
statistically significant improvements in cognitive perfor-
mance and in the activity of daily living in large trials with
AD patients and in other types of dementia (Scott and Goa,
2000; Lilienfeld and Parys, 2000; Blesa et al., 2003; Onor
et al., 2007; Schoenmakers et al., 2009). Accumulating
evidence suggests that nAChR agonists may be superior
to AChE inhibitors in the treatment of AD. It has been
reported that the 7 nAChR is involved in the beta-amy-
oidogenic pathway and plays a neuroprotective role in
onnection with the pathogenesis of AD (Liu et al., 2007;
i et al., 2007; Woodruff-Pak and Gould, 2002). Hence,
he effectiveness of SCT at the different subtypes is of high
nterest. Other beneficial properties of this agent are its
ntioxidant, radical scavenger, and anti-inflammatory ac-
ivities (Shaw et al., 2003; Toda, 2002; Muschietti et al.,
001; Calixto et al., 2003). Oxidative stress, increased
ormation of oxygen radicals, and enhanced lipid peroxi-
ation are induced by i.c.v. injection of beta-amyloid and
re early hallmarks in AD and in its transgenic animal
odels (Sonnen et al., 2008, 2009). Several studies sug-
est that appropriate antioxidants can prevent neurode-
eneration, as reviewed by Sonnen et al. (2008) and Zhao(2009).CONCLUSIONS
In conclusion, we showed that the coumarin SCT amplifies
presynaptic activity-dependent ACh release, enhances
LTP in the CA1 area of the hippocampus, and exerts
cognition-improving properties in cholinergically impaired
and in age-impaired mice. We assume SCT acts as an
agonist at nAChRs and enhances NMDA-dependent LTP.
We suggest that this is the main mechanism of action by
which SCT ameliorates memory.
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